As a trio, three antibiotics that aren’t individually effective against a drug-resistant staph infection killed the deadly pathogen in test tubes and mice.
Researchers say the three-drug combo that killed the bug methicillin-resistant Staphylococcus aureus (MRSA) may also work in people.
“MRSA infections kill 11,000 people each year in the United States, and the pathogen is considered one of the world’s worst drug-resistant microbes,” says principal investigator Gautam Dantas, an associate professor of pathology and immunology at Washington University in St. Louis. “Using the drug combination to treat people has the potential to begin quickly because all three antibiotics are approved by the FDA.”
[Robot cleans hospitals with UV light]
The three drugs—meropenem, piperacillin, and tazobactam—are from a class of antibiotics called beta-lactams that has not been effective against MRSA for decades.
For the new study, published in the journal Nature Chemical Biology, researchers tested and genetically analyzed 73 different variants of the MRSA microbe to represent a range of hospital-acquired and community-acquired forms of the pathogen. The researchers treated the various MRSA bugs with the three-drug combination and found that the treatments worked in every case.
Then, in experiments conducted by collaborators at the University of Notre Dame, the team found that the drug combination cured MRSA-infected mice and was as effective against the pathogen as one of the strongest antibiotics on the market.
“Without treatment, these MRSA-infected mice tend to live less than a day, but the three-drug combination cured the mice,” Dantas says. “After the treatment, the mice were thriving.”
[This ancient remedy actually kills MRSA]
The drugs, which attack the cell wall of bacteria, work in a synergistic manner, meaning they are more effective combined than each alone. Researchers also found that the drugs didn’t produce resistance in MRSA bacteria—an important finding since more and more bacteria are developing resistance to available drugs.
“This three-drug combination appears to prevent MRSA from becoming resistant to it,” Dantas says. “We know all bacteria eventually develop resistance to antibiotics, but this trio buys us some time, potentially a significant amount of time.”
The researchers are also investigating other antibiotics thought to be ineffective against various bacterial pathogens to see if they, too, may work if used in combination with other drugs.
“We started with MRSA because it’s such a difficult bug to treat,” Dantas says. “But we are optimistic the same type of approach may work against other deadly pathogens, such as Pseudomonas and certain virulent forms of E. coli.”
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of General Medical Sciences, and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health funded the work.
